AFI-001

AFI-001 is a novel abuse deterrent opioid extended release formulation of hydrocodone under development with Pernix Therapeutics Inc. The formulation has been developed in multiple strengths and has successfully completed initial pharmacokinetic studies.

Pernix therapeutics releases pharmacokinetic data for zx007 The abuse deterrent features of AFI-001 have also been presented at international meetings;

Pernix Releases Positive in vitro Abuse Deterrent Data for Third Generation Extended Release Hydrocodone ZX007

AFI-001 is currently available for licensing in the United States, Canada, Europe and Japan.

AFI-002

AFI-002 is a novel abuse deterrent extended release stimulant bio-equivalent to a leading ADHD medication. AFI-002 is under development with an undisclosed US partner but Altus retains the rights to the formulation outside of the USA.

AFI-003

AFI-003 is a novel 12hr extended release formulation of a highly addictive opioid bio-equivalent to an existing branded product. AFI-003 is under development with an undisclosed US partner but Altus retains the rights to the formulation outside of the USA.

AFI-004

AFI-004 is a novel 12hr extended release formulation of a highly addictive opioid bio-equivalent to a well-known high volume branded product. AFI-003 is under development with a second undisclosed US partner.

AFI-005

AFI-005 is a novel immediate release formulation of a highly addictive opioid designed to be alcohol resistant and mitigate the potential for abuse via insufflation and injection.